AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Saniona Share Issue/Capital Change 2020

Jan 31, 2020

3195_rns_2020-01-31_d5b617aa-aa66-4f73-982e-e61bc0a0c19c.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

saniona

PRESS RELEASE

January 31, 2020

Change in number of shares and votes in Saniona AB (publ)

During January, the registered number of shares and votes in Saniona AB (publ) ("Saniona") has increased due to the directed issue of shares resolved by the board of directors on January 10, 2020. As of January 31, 2020, the registered number of shares and votes in Saniona amounts to 29,412,519.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona. Mobile: +45 2210 9957, E-mail: [email protected]

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on January 31, 2020.

About Saniona

Saniona is a rare disease biotechnology company focused on research and development company focused on drugs for treatment of eating disorders and diseases of the central nervous system. The Company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the Company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the Company's shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.